FTC Warns Against Endo Privilege Request In Lidoderm MDL
The Federal Trade Commission on Monday said a California federal judge should not allow Endo Pharmaceuticals to selectively waive its privilege in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch,...To view the full article, register now.
Already a subscriber? Click here to view full article